Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DuPont/Bunge soy alliance

This article was originally published in The Tan Sheet

Executive Summary

Joint venture Solae will focus on production of specialty proteins including soy concentrates, lecithins and isolates, partners DuPont and agribusiness company Bunge report. Firms anticipate annual revenues of more than $800 mil. for venture. St. Louis-based Solae is expected to launch this spring...

You may also be interested in...



ADM buys Solae’s soy

Decatur, Ill.-based Archer Daniels Midland has purchased Solae's soy isoflavone business, the firms announce Feb. 15. The acquisition includes "an extensive portfolio of U.S. patents, numerous foreign equivalents and pending applications," ADM says. The deal was reached under a settlement in an isoflavone concentrate patent infringement lawsuit Solae filed against ADM in 2003. Solae was created as a joint venture between Dupont and Bunge in January 2003 (1"The Tan Sheet" Jan. 20, 2003, In Brief)...

ADM’s Novasoy, Amerifit’s Estroven Allegedly Infringe Solae Patents

Solae is seeking to permanently enjoin Archer Daniels Midland and Amerifit Nutrition from making, using or selling soy products it believes infringe on certain company-owned patents, according to a June 3 complaint

Biogen ‘Ready To Launch’ Aducanumab If It Gets The Chance

The company has identified 600 sites of care to treat Alzheimer's patients with aducanumab in the US and is confident on its pricing strategy, management said.

Topics

UsernamePublicRestriction

Register

PS095023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel